A Randomised, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (Affirm-AHF)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ferric carboxymaltose (Primary)
Indications Iron deficiency anaemia
Focus Therapeutic Use
Acronyms Affirm-AHF
Sponsors Vifor; Vifor Pharma

Most Recent Events

28 Aug 2023 Results investigating the interaction between sex and the effects of FCM vs placebo on clinical outcomes, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
13 Apr 2023 Results (n=1107) of a sub-group analysis assessing association between hemoglobin levels and FCM treatment effects published in the Circulation
23 Jul 2022 Results published in the European Journal of Heart Failure

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight